Atlanta: There is no shortage of innovative and potentially ground-breaking science on display at the annual meeting of the American Association for Cancer Research (AACR) that’s currently taking place in Atlanta.
AACR19 Poster Hall melee yesterday afternoon
What is noticeable this year is the large number of scheduling conflicts, i.e. interesting sessions or symposia all going on in parallel and that’s not including the poster sessions, where much of the early work is presented – you could spend much of the meeting in the poster hall alone!
It’s impossible for any outlet to do the meeting justice, so our selection of topics is subjective in nature.
We’ll be posting interviews and more in-depth pieces later, but in this post we take a look at what stood out for us in the Friday/Saturday education sessions we attended and in Sunday oral symposia.
As Frank Sinatra famously sang, “The best is yet to come,” with a tsunami of presentations and posters slated to be heard over the next few days.
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
AACR17 audience in Washington DC
Over the last few years we’ve written a tremendous about primary and acquired resistance, both in oncogenic and immunotherapies, as well as on combination strategies for turning non-responders into responders and overcoming acquired resistance that induces clinical relapse.
These concepts were still on display in Washington DC at the 2017 annual meeting for American Association for Cancer Research (AACR), but beyond those obvious top line points, what are the next round of ideas and tools that cancer researchers are focusing on?
Based on numerous presentations, ad hoc discussions, as well as over a dozen one to one interviews we completed with oncology thought leaders, some useful and encouraging trends emerged.
To learn more insights, subscribers can log in